Focus Partners Wealth Buys 5,896 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Focus Partners Wealth increased its holdings in IQVIA Holdings Inc. by 10.1%, owning 64,052 shares worth approximately $11.3 million as of the last reporting period.
• Research firms have set a new average price target of $229.64 for IQVIA stock, with many analysts maintaining a "buy" or "outperform" rating.
• IQVIA's quarterly earnings exceeded expectations, reporting $2.81 EPS on revenue of $4.02 billion, with a guidance of $11.750-12.050 EPS for FY 2025.

Focus Partners Wealth grew its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 10.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,052 shares of the medical research company's stock after purchasing an additional 5,896 shares during the period. Focus Partners Wealth's holdings in IQVIA were worth $11,293,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of IQV. Pacer Advisors Inc. increased its holdings in shares of IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock worth $153,681,000 after purchasing an additional 854,732 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after acquiring an additional 798,534 shares during the period. Hawk Ridge Capital Management LP bought a new stake in shares of IQVIA in the first quarter worth $77,096,000. Nuveen LLC bought a new stake in shares of IQVIA in the first quarter worth $76,328,000. Finally, GAMMA Investing LLC grew its holdings in shares of IQVIA by 27,448.4% in the first quarter. GAMMA Investing LLC now owns 387,331 shares of the medical research company's stock worth $68,286,000 after acquiring an additional 385,925 shares during the period. Institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

Shares of IQVIA stock traded up $1.00 during trading hours on Tuesday, hitting $186.97. The company's stock had a trading volume of 1,005,530 shares, compared to its average volume of 1,893,994. The business has a 50 day moving average price of $183.32 and a two-hundred day moving average price of $167.24. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $248.03. The company has a market cap of $31.78 billion, a PE ratio of 27.06, a PEG ratio of 2.06 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the previous year, the business earned $2.64 earnings per share. The business's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on IQV shares. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Redburn Partners set a $214.00 price objective on IQVIA in a report on Wednesday, September 3rd. Robert W. Baird boosted their price target on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Citigroup reissued a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Finally, Truist Financial boosted their price target on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Eighteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $229.64.

Insider Activity

In related news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.